# Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

> **NCT06771115** · PHASE2 · COMPLETED · sponsor: **Zomagen Biosciences Ltd.** · enrollment: 176 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** VTX3232 Dose A
- **DRUG:** Placebo
- **DRUG:** VTX3232 Dose A in combination with semaglutide
- **DRUG:** Placebo in combination with semaglutide

## Key facts

- **NCT ID:** NCT06771115
- **Lead sponsor:** Zomagen Biosciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-07
- **Primary completion:** 2025-09-10
- **Final completion:** 2025-09-10
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06771115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06771115, "Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06771115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*